What is the primary mode of action for SSRIs?

What is the primary mode of action for SSRIs?

• A. Block dopamine receptors
• B. Block the reuptake of serotonin
• C. Stimulate serotonin production
• D. Inhibit monoamine oxidase

Answer: (B)

The primary mode of action for selective serotonin reuptake inhibitors (SSRIs) is to block the reuptake of serotonin. This mechanism increases the levels of serotonin available in the synaptic cleft, enhancing neurotransmission and contributing to the alleviation of symptoms associated with depression and anxiety disorders. By preventing the reabsorption of serotonin into the presynaptic neuron, SSRIs allow more serotonin to bind to the postsynaptic receptors. This prolonged presence of serotonin at the synapse is believed to contribute to the therapeutic effects of SSRIs, as serotonin plays a vital role in regulating mood, emotion, and various other physiological functions. Other options involve different neurotransmitter pathways or mechanisms that are not directly associated with SSRIs. For instance, blocking dopamine receptors pertains to antipsychotic medications, stimulating serotonin production relates to other types of treatments not specific to SSRIs, and inhibiting monoamine oxidase refers to MAOIs, another class of antidepressants. Thus, the focus of SSRIs on serotonin reuptake distinguishes their effect in pharmacotherapy for mood disorders.

The primary mode of action for selective serotonin reuptake inhibitors (SSRIs) is to block the reuptake of serotonin. This mechanism increases the levels of serotonin available in the synaptic cleft, enhancing neurotransmission and contributing to the alleviation of symptoms associated with depression and anxiety disorders.

By preventing the reabsorption of serotonin into the presynaptic neuron, SSRIs allow more serotonin to bind to the postsynaptic receptors. This prolonged presence of serotonin at the synapse is believed to contribute to the therapeutic effects of SSRIs, as serotonin plays a vital role in regulating mood, emotion, and various other physiological functions.

Other options involve different neurotransmitter pathways or mechanisms that are not directly associated with SSRIs. For instance, blocking dopamine receptors pertains to antipsychotic medications, stimulating serotonin production relates to other types of treatments not specific to SSRIs, and inhibiting monoamine oxidase refers to MAOIs, another class of antidepressants. Thus, the focus of SSRIs on serotonin reuptake distinguishes their effect in pharmacotherapy for mood disorders.